Cyclo Therapeutics to Proceed with IND Filing for Phase 2 Trial Using Intravenous Trappsol® Cyclo™ in Alzheimer’s Disease
FDA feedback supports Company's Phase 2 development strategy for Alzheimer's disease asset; IND filing on track for H2 2021 GAINESVILLE, Fla. - Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company...
Cyclo Therapeutics Meets Primary Efficacy Endpoint in Phase 1/2 Trial from Intravenous Trappsol® Cyclo™ in Rare Disease Niemann-Pick Type C1 (NPC1)
100% of patients who completed the trial improved or remained stable, and 89% met the efficacy outcome measure of improvement in at least 2 domains of the 17-domain NPC Severity Scale Trial data suggest that Trappsol® Cyclo™ overcomes the NPC1 defect by...
Cyclo Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results
- Multiple value-driving milestones expected throughout 2021- Trappsol® Cyclo™ Niemann Pick Disease Type C (NPC) clinical program on track to imminently report topline results from Phase 1/2 study- Company expects to commence enrollment in pivotal Phase 3...
Cyclo Therapeutics to Participate in Inaugural Emerging Growth Virtual Conference
Presenting Innovative Small and Mid-Cap Companies in Healthcare, Industrials, Electric Vehicles, TMT, and Consumer ProductsGAINESVILLE, Fla. - Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company...
Cyclo Therapeutics Appoints Russ Belden as Acting Chief Commercial Officer
Preeminent biotechnology commercialization leader with over 33 years of industry experience, including 16 years at Genentech with a pivotal role in commercializing products across multiple therapeutic areasGAINESVILLE, Fla. - Cyclo Therapeutics, Inc. (Nasdaq: CYTH)...
Cyclo Therapeutics Receives Positive Opinion from the Paediatric Committee of the European Medicines Agency on the Agreement of a Paediatric Investigation Plan for Trappsol® Cyclo™
GAINESVILLE, Fla. - Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families suffering from disease,...
Cyclo Therapeutics Announces Last Patient Last Visit in Phase 1/2 Trial Evaluating Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C
Topline results from Phase 1/2 study on track for March 2021Individual and cumulative data seen to-date show Trappsol® Cyclo™ to be well tolerated with a favorable safety profile for all dose groups and to have encouraging signals in efficacyPivotal Phase 3...
Cyclo Therapeutics Appoints Gerald F. Cox, MD, PhD as Acting Chief Medical Officer
- Seasoned biotechnology executive with 20-year successful track record of drug development for rare genetic diseases and extensive worldwide regulatory experience - Internationally renowned for clinical development of innovative drugs with broad experience in small...
Cyclo Therapeutics Unveils New Corporate Identity and Reaffirms Commitment to Improving Quality of Life and Providing Hope for Patients and Families
- The evolution of the Company's brand identity aligns with Cyclo Therapeutics' science-based, patient-focus approach to drug development- Company developing cyclodextrin-based products for the treatment of diseases with significant unmet needs, including Niemann-Pick...
Cyclo Therapeutics Presents Positive Data from Clinical Development Program for Lead Candidate, Trappsol® Cyclo™, at WORLDSymposium 2021
Data from ongoing Phase 1 extension study shows improvement in disease features or disease stabilization with home-based intravenous infusions of Trappsol® Cyclo™Phase 1 biomarker 24S-hydroxycholesterol demonstrates clearance of excess cholesterol from the...